LivaNova PLC (NASDAQ:LIVN) Stock Holdings Boosted by Principal Financial Group Inc.

Principal Financial Group Inc. lifted its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 2.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 175,878 shares of the company’s stock after purchasing an additional 4,476 shares during the quarter. Principal Financial Group Inc. owned about 0.32% of LivaNova worth $8,145,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Central Pacific Bank Trust Division raised its holdings in LivaNova by 21.2% during the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock worth $191,000 after buying an additional 720 shares during the period. Captrust Financial Advisors bought a new stake in shares of LivaNova during the 3rd quarter worth about $217,000. Sanctuary Advisors LLC bought a new position in shares of LivaNova in the third quarter valued at approximately $219,000. Edgestream Partners L.P. bought a new stake in LivaNova during the third quarter valued at about $244,000. Finally, GSA Capital Partners LLP bought a new position in LivaNova in the 3rd quarter worth approximately $292,000. 97.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on LIVN. Wolfe Research lowered LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday. StockNews.com downgraded shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Mizuho lowered their price target on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating on the stock in a report on Wednesday. Needham & Company LLC reduced their price objective on shares of LivaNova from $75.00 to $64.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Stifel Nicolaus lowered their target price on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $64.20.

LivaNova Stock Performance

LivaNova stock opened at $41.63 on Friday. LivaNova PLC has a 12-month low of $40.37 and a 12-month high of $64.47. The stock has a 50-day simple moving average of $47.40 and a 200 day simple moving average of $49.53. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $2.26 billion, a price-to-earnings ratio of 99.12 and a beta of 1.00.

Insiders Place Their Bets

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the company’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the sale, the director now owns 7,522 shares in the company, valued at approximately $383,546.78. The trade was a 14.25 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.27% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.